Polypeptide Globular Adiponectin Ameliorates Hypoxia/Reoxygenation-Induced Cardiomyocyte Injury by Inhibiting Both Apoptosis and Necroptosis

Figure 1

Globular adiponectin (gAd) improved cell viability during hypoxia/reoxygenation. (a) Various time points of hypoxia (0, 6, 12, 24, 36, and 48 h) reduced the NRVM viability as demonstrated by MTT assay (). (b) After 12 h of hypoxia and various reoxygenation periods (0, 6, 12, 24, and 36), the cell viability was significantly reduced compared with that of the control group (). (c) The cell viability significantly increased following pretreatment of the cardiomyocytes with various concentrations of gAd (0, 0.5, 1, and 2 μg/ml) (). (d) The 2 μg/ml dose of gAd increased the number of NRVM cells remaining after hypoxia/reoxygenation (). (e) The 2 μg/ml dose of gAd reduced the release of LDH in the culture medium compared with the HR model group (). and vs. the control group; ^# and ^## vs. the H12/R12 group.

(a)

(b)

(c)

(d)

(e)